Cardiovascular adverse events associated with cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone with or without rituximab ((R)-CDOP) in non-Hodgkin’s lymphoma: A systematic review and meta-analysis

Background: The (R)-CDOP combination regimen, based on pegylated liposomal doxorubicin, is increasingly used for elderly patients with non-Hodgkin’s lymphoma. However, the cardiotoxicity and efficacy of the (R)-CDOP regimen compared with conventional anthracyclines have not been demonstrated in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Bin, Shen, Longfei, Ma, Ying, Qi, Jia, Li, Yulin, Wang, Zhihao, Han, Lu, Zhong, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752891/
https://www.ncbi.nlm.nih.gov/pubmed/36532720
http://dx.doi.org/10.3389/fphar.2022.1060668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752891/
https://www.ncbi.nlm.nih.gov/pubmed/36532720
http://dx.doi.org/10.3389/fphar.2022.1060668

Ejemplares similares